Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Is CJC-1295 Prohibited by WADA?

CJC-1295 is named in WADA section S2.2.4 and is prohibited in and out of competition under the 2026 Prohibited List.

Why we wrote this. Athletes need the current named WADA entry and real enforcement examples, not a retailer's interpretation.

In this article (5 sections)
  1. Where CJC-1295 sits on the 2026 list
  2. Prohibited at all times means exactly that
  3. What the rule means for no-DAC products
  4. What athletes should verify
  5. What we do not yet know

Yes. CJC-1295 is prohibited in sport under the 2026 World Anti-Doping Agency Prohibited List. It appears by name in section S2.2.4 among growth-hormone-releasing factors, and section S2 is prohibited at all times, both in and out of competition[1]. Athletes should not treat an online 'research' label, a no-DAC label, or use outside competition as a loophole.

USADA has enforced the rule in cases involving CJC-1295. A 2021 cycling case and a 2020 weightlifting case each described the substance as a non-specified peptide hormone and imposed four-year periods of ineligibility[2][3]. A 2025 triathlon case also identified CJC-1295 as prohibited at all times and addressed promotion of prohibited peptides[4].

Where CJC-1295 sits on the 2026 list

The 2026 list places CJC-1295 in S2.2.4, growth-hormone-releasing factors. The entry names GHRH and its analogues and gives CJC-1293, CJC-1295, sermorelin, and tesamorelin as examples[1]. CJC-1295 is therefore not captured only by a broad 'related substances' phrase. It is an explicit example within the class.

The words 'including, but not limited to' still matter. The list does not have to name every analogue or marketing synonym for the class rule to apply. That catch-all prevents minor renaming or a closely related compound from becoming automatically permitted. For CJC-1295 itself, however, the named entry already answers the basic status question.

The rule is class-based because CJC-1295 acts on the growth-hormone axis. Human research found sustained increases in growth hormone and IGF-1 after the long-acting compound[5]. The scientific paper explains the biological context, while WADA's current list controls the anti-doping status.

Prohibited at all times means exactly that

For S2 substances, the ban applies in competition and out of competition. An athlete can therefore face a rule violation based on use or possession outside an event window, depending on the applicable code and facts. Waiting until an off-season does not change the classification. Neither does calling the vial a research chemical.

USADA's 2021 Vahe Aivazian decision says he possessed and used or attempted to use ten prohibited substances, including CJC-1295. USADA classified CJC-1295 as a non-specified substance in the S2 class and reported a four-year period of ineligibility[2]. This is an enforcement example, not a prediction that every case receives the same sanction. Sanctions depend on the rule, evidence, conduct, and case-specific findings.

The Scott Hisaka decision likewise concerned possession of products containing several prohibited substances, including CJC-1295. USADA stated that those substances were prohibited at all times and imposed a four-year period of ineligibility[3]. The examples show that possession and documentary evidence can matter even when an article is not describing a positive analytical test.

What the rule means for no-DAC products

Anti-doping laboratories have developed methods that treat CJC-1295 and CJC-1295 with drug affinity complex as separate analytical targets. The research paper still describes administration of GHRH and its synthetic analogues as prohibited by WADA[6]. A seller's no-DAC wording is therefore not evidence that a product falls outside S2.

Product identity is a separate risk. A label can be inaccurate, a blend can contain undeclared ingredients, and contamination can still expose an athlete to an anti-doping violation. PeptideMethods does not authenticate products or provide clearance for competition. Athletes should use their anti-doping organization and formal therapeutic-use process for medication questions.

For molecule background, see the CJC-1295 evidence page. Our CJC-1295 human-study dosing explainer explains why trial exposure is not a self-use protocol. The CJC-1295 and ipamorelin explainer keeps combination claims separate.

The separate ipamorelin reference page matters when a blend lists both substances. WADA names ipamorelin under growth-hormone secretagogues in the same S2.2.4 section, so a combination does not remove the prohibition[1].

What athletes should verify

Check the current WADA list and the rules of the organization with authority over your sport. If a legitimate medical need is involved, contact the relevant anti-doping body before use and ask about the therapeutic use exemption process. A clinician's prescription does not automatically equal anti-doping permission, and a retailer's description is not an authoritative status check.

What we do not yet know

A public article cannot determine the contents of a particular vial, predict a laboratory result, or decide an individual case. Anti-doping rules and documents are updated. This page reflects the 2026 list inspected on October 26, 2026, and should be rechecked against WADA and the athlete's anti-doping organization before any decision.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Regulatory disclaimer: This page reflects our understanding of the regulatory status as of October 26, 2026. Regulations change. Verify with the official regulator before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.

Frequently asked

Is CJC-1295 banned by WADA in 2026?

Yes. The 2026 Prohibited List names CJC-1295 in section S2.2.4 among growth-hormone-releasing factors.

Is CJC-1295 prohibited out of competition?

Yes. WADA class S2 is prohibited at all times, which includes in-competition and out-of-competition periods.

Is CJC-1295 without DAC permitted?

A no-DAC marketing label is not evidence of permission. WADA prohibits GHRH analogues as a class, and anti-doping research treats CJC-1295 variants as analytical targets.

Has USADA sanctioned athletes in cases involving CJC-1295?

Yes. Public USADA decisions include cycling and weightlifting cases that named CJC-1295 among prohibited substances and imposed four-year periods of ineligibility.

Sources

  1. [1]WADA 2026 Prohibited List, section S2.2.4Tier 1 · primary↩
  2. [2]USADA: Vahe Aivazian accepts anti-doping sanction (2021)Tier 1 · primary↩
  3. [3]USADA: Scott Hisaka accepts anti-doping sanction (2020)Tier 1 · primary↩
  4. [4]USADA: Anthony McCauley accepts anti-doping sanction (2025)Tier 1 · primary↩
  5. [5]Teichman et al. (2006): Long-acting CJC-1295 in healthy adults (PMID 16352683)Tier 1 · primary↩
  6. [6]Memdouh et al. (2021): Detection of CJC-1295 analogues (PMID 34665524)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars